Status:
NO_LONGER_AVAILABLE
Expanded Access Program Using IMM-101 for Patients With Advanced Pancreatic Cancer
Lead Sponsor:
Impatients N.V. trading as myTomorrows
Collaborating Sponsors:
Immodulon Therapeutics Ltd
Conditions:
Pancreas Cancer
Pancreatic Cancer
Eligibility:
All Genders
18+ years
Brief Summary
An Expanded Access Program for IMM-101 for patients with advanced pancreatic cancer.
Detailed Description
IMM-101 is a suspension of heat-killed whole cell Mycobacterium obuense. Since it is a heat-killed preparation, treatment is not associated with the potential side-effects of delivering live or attenu...
Eligibility Criteria
Inclusion
- This Expanded Access Program is available for patients of 18 years or older with advanced pancreatic cancer for whom, in the opinion of their treating physician, other treatment options or clinical trials in this indication are unsuitable.
Exclusion
- Female patient of child-bearing potential who is not, in the opinion of the physician, using an approved method of birth control (e.g., physical barrier \[patient and partner\], contraceptive pill or patch, spermicide and barrier, or intrauterine device \[IUD\]).
Key Trial Info
Start Date :
Trial Type :
EXPANDED_ACCESS
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04137822
Last Update
August 14 2020
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
France
Paris, France
2
UK
London, United Kingdom